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Confronting Trade-Offs In Health Care: Harvard Pilgrim Health Care's Organizational Ethics Program
Ethical analysis can provide practical decision support for health care organizations.
by James E. Sabin and David Cochran ABSTRACT: Patients, providers, and policy leaders need a new moral compass to guide them in the turbulent U.S. health care system. Task forces have proposed excellent ethical codes, but these have been seen as too abstract to provide guidance at the front lines. Harvard Pilgrim Health Care's ten-year experience with an organizational ethics program suggests ways in which health care organizations can strengthen transparency, consumer focus, and overall ethical performance and contribute to the national health policy dialogue. n t h e t u r b u le n t U.S. health care system, patients, providers, policy leaders, and other stakeholders need a new moral compass to navigate between the Scylla of rising costs and the Charybdis of patients' needs and expectations. Because so much of health care is shaped by organizations, traditional medical ethics, which is built around the doctor-patient dyad, cannot alone supply the needed compass.
For ten years, Harvard Pilgrim Health Care (HPHC), a not-for-profit health insurance company serving 1,000,000 members in Massachusetts, New Hampshire, and Maine, has supported an organizational ethics program that has advised on the full range of issues confronting contemporary health plans. This paper describes the process by which HPHC has approached the ethical dimensions of its work, some of the policy guidance it has derived, and potential lessons for other organizations.
HPHC takes a hands-on approach in which organizational leaders seek consultation on the ethical dimensions of operational and policy issues they are dealing with.
Program Development
The program started after HPHC was formed by the 1995 merger of Harvard Community Health Plan, a not-for-profit health maintenance organization (HMO), with Pilgrim Health Care, a not-for-profit independent practice association (IPA). Both partners were respected as ethical organizations, but their cultures were divergent enough that each feared the other might contain "unethical" components, and the environmental demand for cost reductions was seen as creating major ethical challenges. The medical director and chief executive officer (CEO) jointly an-nounced the new program as follows:
Each day we are bombarded with stories raising public awareness of the basic tension at the heart of the health care debate-preserving a health care system which supports the best interests of individual patients while balancing society's need to ensure affordable, accessible, quality health care for an entire population within finite resources.… The goals of the Ethics Program are to:
Promote increased organizational skill at identifying and addressing the ethical dimensions of key policy, operational and budgetary decisions…Assure that Harvard Pilgrim Health Care is prepared to address the ethical aspects of issues being forced by our competitive market with confidence that our processes withstand public scrutiny.…Attain national recognition as managed care leaders in this initiative.
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The initial director, whose background was in strategic planning as well as ethics, interviewed HPHC leaders and board members about the central ethical issues facing the organization and how to structure the new program. There was a clear consensus that the program should be consultative with no "must approve" role. As a result, she defined the program as a "decision-support" function and formed an ethics advisory group (EAG) as its hub.
The EAG is the most distinctive feature of HPHC's approach to ethics. The group includes HPHC staff, consumers, physicians from the network, purchasers and brokers, and external health system and ethics leaders. The group addresses issues brought to it by HPHC leaders-referred to as the "customer"-who are responsible for the area in question.
EAG meetings typically have twenty to twenty-five participants and last for two hours. The ethics program director (now James Sabin) prepares a "case" that gives background, identifies the customer's questions, and summarizes relevant precedents. After the meeting, the director writes a report presenting the key perspectives that emerge from the deliberations. The report is posted on the HPHC Intranet site and the Web site for affiliated providers.
As of early spring 2007, the EAG has held eighty-four meetings. For this paper we have selected two central themes to illustrate the wide array of topics the program has addressed: transparency about decisions and policies, and consumer-directed health care.
Transparency
n The case of Viagra. The Food and Drug Administration (FDA) approval of Viagra in 1998 led to a meeting that has provided important perspectives on organizational transparency. 2 The team deciding about Viagra coverage posed three sets of questions: (1) Should HPHC cover Viagra? If not, why not? (2) Given cost considerations, if HPHC covers Viagra, should coverage be limited? If so, with what rationale? (3) How should HPHC present its decisions to members, providers, and the public?
Several participants described Viagra as a "life-style drug" and suggested not covering it. At this point, a female leader representing an employer that provided HPHC insurance for its employees spoke with force: "I can't believe that at the end of the twentieth century-after all that Freud taught us-that we are talking as if sexuality were an optional matter of 'lifestyle.' Sex is an essential aspect of our being. To reduce the ability to have intercourse to the status of a 'life-enhancing' activity is to belittle a patient's valid desire to restore a basic function."
These comments led the EAG to see Viagra as an innovation that should not be trivialized as a "lifestyle choice." It suggested that Viagra should be allowed to compete for coverage within the overall organizational budget but that the value it provided should be compared to the value provided by alternative uses of funds.
The EAG believed that limiting coverage because of cost was an ethically acceptable option. But if HPHC chose this option, the EAG felt that the organization should explicitly acknowledge the cost containment rationale. How could HPHC be trusted if it was not transparent about its policies, especially when the rationale involved the controversial area of cost? 3 After the meeting, HPHC decided to cover four Viagra pills a month. As the head of the Pharmacy and Therapeutics (P&T) Committee put it, "How often you have intercourse is up to you and your partner. How many Viagra pills you receive is up to you and your doctor. How many pills your insurance pays for is up to the health plan." Viagra was newsworthy in 1998. HPHC's decision drew extensive media attention. Here is how the medical director discussed the policy with the press: "I don't want to be in the position of saying how often people should have intercourse. We are not telling physicians they can write prescriptions for only four pills. They can write for thirty or ninety or whatever. What we are saying is that we will pay for only four a month."
As to why Harvard Pilgrim settled on four pills as opposed to, say, eight, [Joseph] Dorsey admits there is no scientific logic to that number. "It demonstrates a commitment to using the resource pool to help make it possible for people to use the medication…but it also reflects the fact that Viagra is too expensive for us to pay for unlimited use." 4 The medical director's commitment to transparency can also be seen in comparing the draft and final version of a memo to physicians in the HPHC network:
Draft: The expense of this product also played a part in the coverage decisions.… Paying for an unlimited number of Viagra tablets would divert [limited resources] away from medically necessary, lifesaving medications.
The medical director felt that (1) the word "also" played down the role of cost and (2) reference to "lifesaving medications" misleadingly implied that without the limit on Viagra, other members might be deprived of life itself! Here is his revision of the draft he received:
Final: The expense of this product played a major part in the coverage decision.… Paying for an unlimited number of Viagra tablets would divert [limited resources] away from other uses.
A Boston Globe editorial, which stated that "Massachusetts HMOs have devised a policy that reasonably balances medical and cost considerations," reinforced HPHC's commitment to transparency. 5 HPHC concluded that being explicit and educative made it likelier that controversial policies such as the one it adopted for Viagra would be understood, trusted, and accepted as fair, even by those for whom the policy was disappointing.
n Provider performance. Four years later, in a meeting focused on giving members data on provider quality, the EAG was asked for further consultation about transparency:
In making comparative provider data available to members…what values are most relevant to deciding when data are "good enough"?
The EAG reaffirmed its commitment to transparency but treated openness as one among many values, not as a supreme value trumping all others:
The EAG saw the provision of comparative data as a tool for member education, and saw member education as a tool for improving quality through improved decision-making.…With regard to deciding how good quality data must be for HPHC to [make them public], the EAG recommended using two values in making this decision. First, it is important to make a start. Currently available data are far from perfect, but it will improve faster by beginning to use it… That said, the EAG identified cultivating trust in the integrity of the process as the key value to use in deciding when data are "good enough" to use.
The customers asked for advice about giving information as a "report card" for all providers compared to an "honor roll" of high performers:
When the EAG considered the relative risks of inaccurate "report card" information versus inaccurate "honor roll" information, the honor roll approach seemed to be the better way to start. If competent providers were given a bad grade because of faulty information…they and their patients could suffer significant injury, and the whole effort to develop comparative information could be set back. If a high performing provider were erroneously left off the honor roll because of faulty information, however, less harm would be done.
The EAG has encouraged transparency as an end in itself and as a means for promoting other values. An open relationship with constituents respects them as individuals. As in the Viagra example, transparency contributes to trust. And, as in the deliberation about comparative provider information, transparency can improve enrollees' decision making.
Consumer-Directed Health Care
By 2001 the market was moving toward "consumer-directed" products and away from insurer-and physician-led managed care. 6 During 2001-2006 the EAG devoted six meetings to the ethical dimensions of HPHC's response to purchasers' demand for moreaffordable health insurance. In July 2002 the leader responsible for developing consumerdirected products posed two sets of questions to the EAG: (1) What important values are potentially placed at risk by the new products? How can these risks be minimized? (2) What important values are potentially enhanced by the new products? How can these opportunities be developed most fully?
With regard to risks, the EAG emphasized the potential impact of deductibles on lowincome populations:
The ideology behind the national movement towards increased cost sharing is that having consumers "put skin in the game" can decrease a "cost-unconscious entitlement mentality." However, especially for less affluent members, increased copayments and deductibles are not so much opportunities for learning how to distinguish marginal from important care as barriers to care itself.… While society does not regard it as a failure of justice if someone cannot afford a new car [,] … as an affluent society we do and should regard financial barriers to needed health care as unjust. Increased cost sharing is a blunt instrument, likely to constrain needed care as well as optional or marginally valuable care.
The customer, however, asked the EAG to advise about how to minimize risks, not simply to lament about its concerns. In 2001, in its first consideration of consumer-directed products, the EAG had "suggested that incentives could be aligned with health-promoting behaviors." HPHC designed the new products with preventive care and much of primary care not subject to the deductible. In 2002 the EAG added further advice about protecting important values:
To make [the new products] an opportunity for true consumer directed health care and not simply a vehicle for shifting costs to consumers, consumers need the right information at the right time. Employers are key information sources when consumers are deciding which insurance choices to make. Providers are key information sources when consumers are deciding about treatment alternatives.… HPHC should use its strengths as a provider of education to encourage members to use the financial incentives built into [the new products] as an opportunity for thinking deeply about the value of medical care alternatives. Virtually all members are discerning consumers in other areas of their lives. HPHC should offer educational tools to help them become more discerning consumers in health care.
The EAG saw the possibility that deductibles could lead patients to become more active co-managers of the quest for value for money in health care as the central ethical opportunity. No one likes limits, but limits set in accord with clinical knowledge and members' preferences have the best chance of being understood and endorsed as fair.
The EAG emphasized the importance of…gather-ing data about the new products [and] endorsed the cautious, careful approach [that HPHC was taking]. It strongly endorsed seeing the new products as part of a national experiment based on a hypothesis about what shifting more choice and financial risk to consumers might accomplish. HPHC can pursue its aspiration to being "the most trusted name in health care" by being a leader in learning from and articulating the lessons that emerge from the national experiment [with consumer-directed health care].
HPHC has tried to be "a leader in learning" in two central ways. First, it used its own experience as an employer introducing a highdeductible choice for employees as a "laboratory" for studying how employers and employees can engage in new forms of conversation about seeking value in health care and documented that experience in a widely circulated annual report. 7 Second, the Harvard Medical School Department of Ambulatory Care and Prevention, jointly sponsored by Harvard Medical School and HPHC, is studying the impact of consumer-directed products on both needed and marginal care. Initial findings were published earlier this year. 8 
Practical Lessons
Although the health care system is increasingly driven by public agencies and private organizations, medical ethics is still largely approached through a dyadic doctor-patient model. Distinguished task forces have broadened the focus to include all stakeholders, but their efforts have not been widely applied at the front lines because the codes feel abstract to stakeholders working under conditions of time pressure and imperfect information. 9 HPHC's tenyear experience supplements the codes with practical lessons about how to make ethical analysis a meaningful contributor to organizational functioning.
n Make tough allocation decisions. Health care organizations regularly face tough allocation decisions. HPHC asks its ethics program to help tease out the values dimensions of these decisions and help leaders deal with them in new and better ways. Just as there are ways of working out other business processes, there are ways for organizations to work through the ethical dimensions of what they do.
n Include stakeholders. HPHC has applied a stakeholder-based approach to ethics by creating an advisory body with vigorous voices from consumers, providers, employers, staff, and leaders from the policy community. The advisory group enters into dialogue with HPHC leaders who seek consultation. A facilitator with training in ethics develops background materials, leads the meeting, and circulates an analytic report to the organization and its constituents.
The outcome is a combination of consultation advice, case precedents, and moral stories that gradually become part of organizational culture. The Viagra case conveys a strong message about transparency. HPHC has made openness about cost and quality a hallmark of its approach. The multiple discussions of consumer-directed health care led to the conclusion that high-deductible insurance represents a national health policy experiment that requires study to see how it actually performs. n Ethical analysis for practical decision support. Perhaps the most important potential lesson for policymakers is that ethical analysis can provide practical decision support for health care organizations. For this to happen, leadership must believe that systematic attention to values can promote organizational success, and the ethics activities must fit the organization and its environment. 10 Health plans mediate among patients, providers, purchasers, and the public, so, for HPHC, an advisory body with vigorous participation from these groups has elicited organizational recognition and support. Hospitals, extended care facilities, and large group practices will require approaches geared to their own environments and cultures.
Health care organization-level ethics activities are in an early phase of development. Hospital ethics committees are just beginning to address organizational issues. Faith-based systems, however, commonly have mission offices to link mission to organizational strategy. Key conditions for adaptation of the HPHC experience appear to be: support from senior leaders; galvanizing issues that elicit organizational concern; a facilitator with ethics and organizational skills; involvement of key stakeholder groups in deliberations; and being structured to provide decision support and education. 11 At HPHC, the EAG meetings, which are held every two months, are open to all interested staff, and close to 10 percent of staff members have attended at least one meeting. HPHC values the program for its impact S c i e nc e p r o g r e s se s through a combination of theoretical reflection and experimental observation in multiple laboratories. In similar fashion, health care ethics will advance if we combine conceptual analysis with careful observation in the "laboratories" of health plans, hospitals, and other health care organizations.
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